Protalix BioTherapeutics, Inc.
PLX.TA
Tel Aviv Stock Exchange732.50
ILA
- -
- -
Protalix BioTherapeutics, Inc.
PLX.TA
(Tel Aviv Stock Exchange)
Recent
price
732.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Protalix BioTherapeutics, Inc. (NYSE American: PLX; TASE: PLX.TA) is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins for rare diseases using its proprietary plant cell-based ProCellEx expression system; its approved products include Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for adult patients with Fabry disease partnered globally with Chiesi Farmaceutici S.p.A., and Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease licensed worldwide to Pfizer Inc. excluding Brazil where Protalix retains rights under agreements with Fundação Oswaldo Cruz; the pipeline features PRX-115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout which completed a successful Phase I trial in 2024 with plans for Phase II in the second half of 2025, PRX-119, a long-acting DNase I for NETs-related diseases, and preclinical programs targeting renal rare diseases with plant-based drug delivery systems. Founded in 1993 and headquartered in Carmiel, Israel, with U.S. operations in Hackensack, New Jersey, the company conducts geographic operations in the United States, Europe, Australia, Canada, Brazil, Israel, Russia, and Turkey. Recent developments include the European Medicines Agency validation in 2024 of Chiesi's variation submission for Elfabrio seeking less frequent every-four-weeks dosing to reduce patient treatment burden, record 2024 product sales revenue of $53 million reflecting 31% growth across partnerships with Chiesi, Pfizer, and Brazil, full repayment of outstanding convertible notes achieving a debt-free balance sheet, appointment of Gilad Mamlok as Chief Financial Officer in August 2025, and addition to the Russell 3000 and Russell 2000 Indexes.